CandlesenseCandlesense
LLY•benzinga•

Lilly's Tirzepatide Delivered Up To 22.5% Weight Loss In Adults With Obesity Or Overweight In Surmount-1; Co. Reports 'Tirzepatide met both co-primary endpoints of superior mean percent change'

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on April 28, 2022 by benzinga

← Back to LLY News
    Lilly's Tirzepatide Delivered Up To 22.5% Weight Loss In Adults With Obesity Or Overweight In Surmount-1; Co. Reports 'Tirzepatide met both co-primary endpoints of superior mean percent change' | LLY Stock News | Candlesense